JP2007515949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515949A5 JP2007515949A5 JP2006539632A JP2006539632A JP2007515949A5 JP 2007515949 A5 JP2007515949 A5 JP 2007515949A5 JP 2006539632 A JP2006539632 A JP 2006539632A JP 2006539632 A JP2006539632 A JP 2006539632A JP 2007515949 A5 JP2007515949 A5 JP 2007515949A5
- Authority
- JP
- Japan
- Prior art keywords
- tgf
- antagonist
- cancer
- tumor
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52039803P | 2003-11-13 | 2003-11-13 | |
| US55795104P | 2004-03-31 | 2004-03-31 | |
| PCT/US2004/036651 WO2005050200A2 (en) | 2003-11-13 | 2004-11-04 | Screening assays and methods of tumor treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007515949A JP2007515949A (ja) | 2007-06-21 |
| JP2007515949A5 true JP2007515949A5 (cg-RX-API-DMAC7.html) | 2007-12-20 |
Family
ID=34623132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539632A Withdrawn JP2007515949A (ja) | 2003-11-13 | 2004-11-04 | スクリーニングアッセイ及び腫瘍治療の方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060015952A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1682890A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007515949A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20060127409A (cg-RX-API-DMAC7.html) |
| AR (1) | AR046832A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004292180A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0416305A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2542215A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL174916A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20062715L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2006120483A (cg-RX-API-DMAC7.html) |
| TW (1) | TW200526957A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005050200A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005053682A2 (en) * | 2003-11-26 | 2005-06-16 | Arqule, Inc. | Use of beta-lapachone for protecting against radiation injury |
| CN1961003B (zh) * | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7412026B2 (en) * | 2004-07-02 | 2008-08-12 | The Board Of Regents Of The University Of Oklahoma | Phase-contrast x-ray imaging systems and methods |
| US20080082367A1 (en) * | 2006-09-29 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
| US20080082359A1 (en) * | 2006-09-29 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of State Of Delaware | Computational systems for biomedical data |
| US7853626B2 (en) | 2006-09-29 | 2010-12-14 | The Invention Science Fund I, Llc | Computational systems for biomedical data |
| US10546652B2 (en) * | 2006-09-29 | 2020-01-28 | Gearbox Llc | Computational systems for biomedical data |
| US8122073B2 (en) | 2006-09-29 | 2012-02-21 | The Invention Science Fund I | Computational systems for biomedical data |
| US10503872B2 (en) | 2006-09-29 | 2019-12-10 | Gearbox Llc | Computational systems for biomedical data |
| US20080091730A1 (en) * | 2006-09-29 | 2008-04-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
| US10068303B2 (en) | 2006-09-29 | 2018-09-04 | Gearbox Llc | Computational systems for biomedical data |
| US20080082583A1 (en) * | 2006-09-29 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
| US20080109484A1 (en) * | 2006-09-29 | 2008-05-08 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
| US10095836B2 (en) * | 2006-09-29 | 2018-10-09 | Gearbox Llc | Computational systems for biomedical data |
| US8491890B2 (en) * | 2008-07-09 | 2013-07-23 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| NZ623273A (en) | 2008-12-05 | 2015-09-25 | Abraxis Bioscience Llc | Sparc binding scfvs |
| US20120294868A1 (en) * | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| RU2012107535A (ru) * | 2009-07-30 | 2013-09-10 | Антисенс Фарма Гмбх | КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β |
| WO2011053743A1 (en) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Pcsk9 immunoassay |
| EP3117709B1 (en) * | 2010-03-12 | 2018-08-01 | Genzyme Corporation | Combination therapy for treating breast cancer |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| WO2013173827A2 (en) | 2012-05-18 | 2013-11-21 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| KR101479543B1 (ko) * | 2013-03-15 | 2015-01-07 | 서강대학교산학협력단 | Tfg-tec 융합 컨스트럭트를 이용한 종양 질환의 예방 또는 치료용 물질의 스크리닝 방법 및 이의 용도 |
| JP6805428B2 (ja) | 2014-04-27 | 2021-01-06 | フェイムウェイヴ リミテッド | Ceacam1に対するヒト化抗体 |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| EP3356512B1 (en) | 2015-10-02 | 2021-03-31 | Wake Forest University Health Sciences, Inc. | Methods and apparatus for modeling cancer metastasis in vitro |
| EP3368571B1 (en) * | 2015-10-30 | 2022-12-07 | The Regents of The University of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| JP7763450B2 (ja) | 2018-02-02 | 2025-11-04 | ウェイク・フォレスト・ユニバーシティ・ヘルス・サイエンシーズ | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
| KR102917630B1 (ko) | 2018-08-21 | 2026-01-27 | 앨버트 아인슈타인 컬리지 오브 메디신 | 인간 Tim-3에 대한 모노클로날 항체 |
| US12260607B2 (en) | 2018-12-15 | 2025-03-25 | The Brigham And Women's Hospital, Inc. | Augmented digital microscopy for lesion analysis |
| CN111088227A (zh) * | 2019-12-31 | 2020-05-01 | 广州航华生物医药科技有限公司 | 一种细胞分离培养液和t细胞分离培养的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5087799A (en) * | 1998-07-06 | 2000-01-24 | Beth Israel Deaconess Medical Center | Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| WO2001057061A1 (en) * | 2000-02-04 | 2001-08-09 | California Pacific Medical Center Research Institute | Novel use of ribozymes to block gene expression |
| US20010046502A1 (en) * | 2000-02-04 | 2001-11-29 | The Board Of Trustees Of The University Of Illinois | Animal model for testing immunotherapies of spontaneous metastatic disease |
| CA2298737A1 (en) * | 2000-02-10 | 2001-08-10 | Manikkam Suthanthiran | 2167334tgf-.beta. antagonists to inhibit tumor cell formation or progression |
| US6632979B2 (en) * | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US6767541B2 (en) * | 2000-03-20 | 2004-07-27 | The Regents Of The University Of California | HER-2/neu overexpression abrogates growth inhibitory pathways |
| US20030125251A1 (en) * | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
-
2004
- 2004-11-04 AU AU2004292180A patent/AU2004292180A1/en not_active Abandoned
- 2004-11-04 EP EP04810283A patent/EP1682890A2/en not_active Withdrawn
- 2004-11-04 JP JP2006539632A patent/JP2007515949A/ja not_active Withdrawn
- 2004-11-04 KR KR1020067011504A patent/KR20060127409A/ko not_active Withdrawn
- 2004-11-04 BR BRPI0416305-2A patent/BRPI0416305A/pt not_active IP Right Cessation
- 2004-11-04 WO PCT/US2004/036651 patent/WO2005050200A2/en not_active Ceased
- 2004-11-04 RU RU2006120483/15A patent/RU2006120483A/ru not_active Application Discontinuation
- 2004-11-04 US US10/981,356 patent/US20060015952A1/en not_active Abandoned
- 2004-11-04 CA CA002542215A patent/CA2542215A1/en not_active Abandoned
- 2004-11-05 TW TW093133935A patent/TW200526957A/zh unknown
- 2004-11-05 AR ARP040104077A patent/AR046832A1/es unknown
-
2006
- 2006-04-10 IL IL174916A patent/IL174916A0/en unknown
- 2006-06-12 NO NO20062715A patent/NO20062715L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Halvorson et al. | A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone | |
| RU2006120483A (ru) | Скрининг-анализы и способы лечения опухоли | |
| Abdollahi et al. | Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis | |
| Higo et al. | Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy | |
| Kim et al. | Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer | |
| Kuefner et al. | DNA double-strand breaks and their repair in blood lymphocytes of patients undergoing angiographic procedures | |
| RU2748549C2 (ru) | Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата | |
| Xiao et al. | Postoperative tumor treatment strategies: From basic research to clinical therapy | |
| EP2908862A1 (en) | Cancer cell trap | |
| AU2017214230A1 (en) | Copanlisib biomarkers | |
| WO2018067545A1 (en) | Chondroprotective nanoparticles for the treatment of osteoarthritis | |
| Terashima et al. | Beneficial effect of maintaining hepatic reserve during chemotherapy on the outcomes of patients with hepatocellular carcinoma | |
| Wang et al. | The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging | |
| JP2025537840A (ja) | 選択的エストロゲン受容体分解薬(serd)による乳がんの治療方法 | |
| Sobol et al. | Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma | |
| Ko et al. | The use of chemokine-releasing tissue engineering scaffolds in a model of inflammatory response-mediated melanoma cancer metastasis | |
| BRPI0715062A2 (pt) | mÉtodos para determinar uma resposta de um indivÍduo mamÍfero que tem cÉlulas de tumor de melanoma ao tratamento com um agente inibidor de melanoma, para avaliar a eficÁcia de um agente inibidor de melanoma para tratar melanoma em um indivÍduo mamÍfero que tem melanoma, para determinar se um paciente deve continuar a receber tratamento com um agente inibidor de melanoma e para identificar agente que tÊm utilidade no tratamento de melanoma | |
| Lan et al. | Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers | |
| Kawaragi et al. | Teriparatide does not exacerbate bone metastases in breast cancer bone metastasis model | |
| Dreicer et al. | A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer | |
| JP7796651B2 (ja) | ラベルをハンガーとして用いる薬剤直接輸液装置および方法 | |
| Aung et al. | Osteogenic sarcoma in children and young adults | |
| CN109069632A (zh) | 用于治疗结直肠癌的雷莫芦单抗和merestinib的组合 | |
| Rasulova et al. | Effectiveness of Bone Metastases Treatment by Sm–153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience | |
| Zaharie et al. | Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient |